Statement of stand-alone Financial Results for the quarter and nine months ended 31st December, 2013
Rs. lakhs
THREE MONTHS ENDED
(REVIEWED)
YEAR-TO-DATE FIGURES
(REVIEWED) FOR THE
NINE MONTHS PERIOD
ENDED ON
PARTICULARS
PART I : STATEMENT OF STAND-ALONE
RESULTS
01. Gross Sales / Income from Operations
Less : Excise Duty
Less : Sales Tax
Net Sales / Income from Operations
02. Other Operating Income
03. TOTAL INCOME FROM OPERATIONS
04. EXPENDITURE
a) Cost of materials consumed
b) Purchases of stock-in-trade
c) Changes in inventories of finished goods, work-inprogress and stock-in-trade
d) Employee benefits expense
e) Depreciation and amortization expense
f) Other Expenses
TOTAL EXPENSES
05. Profit / (Loss) from Operations before other income,
finance costs and exceptional items
06. Other Income
07. Finance costs
08. Exceptional Items
09. Profit / (Loss) from ordinary activities before tax
10. Tax expense, including deferred tax
11. Net Profit / Loss (-) from ordinary activities after tax
12. Paid-up Equity Share Capital (each share of Rs. 10/face value)
13. Reserves excluding revaluation reserves as per
Balance Sheet of previous accounting year
14. Earnings per share – Basic and diluted EPS before
and after extraordinary item (Rs.) – non-annualized
Part II : Select Information
15. Public Shareholding:
a) Number of Shares
b) Percentage of Shareholding
16. Promoters and Promoter Group Shareholding
a) Pledged / Encumbered –
b) Non – encumbered – No. of shares
Percentage (as a % of the total shareholding of
promoter and promoter group)
Percentage (as a % of the total share
capital of the company)
Dated at Hyderabad, this, the 13th day of February, 2014.
for and on behalf of the Board of Directors,
NATCO Pharma Limited
31-DEC2013
30-SEP2013
31-DEC2012
31-DEC2013
31-DEC2012
YEAR ENDED
(AUDITED)
31-MAR-2013
16347
321
321
15705
1718
17423
14019
375
269
13375
1631
15006
13788
508
229
13051
1980
15031
44620
987
868
42765
4146
46911
41120
1687
823
38610
2984
41594
54656
2122
1101
51433
4492
55925
4485
-908
3755
-227
5064
55
-527
12111
-1410
13289
488
-1436
18063
558
-2125
2492
686
5531
12286
5137
2214
656
4601
10999
4007
1878
550
3822
10842
4189
6911
1983
14304
33899
13012
6449
1448
10513
30751
10843
8536
1984
15201
42217
13708
105
877
4365
1123
3242
3307
177
957
3227
358
2869
3137
570
731
541
3487
1050
2437
3137
632
2792
10852
2467
8385
3307
991
1742
1159
8933
2291
6642
3137
1194
2512
1158
11232
3419
7813
3137
10.14
10.14
9.15
9.15
7.79
7.79
26.55
26.55
21.29
21.17
50621
25.02
24.91
15,311,593
46.30
13,611,493
43.39
13,603,193
43.36
15,311,593
46.30
13,603,193
43.36
13,594,593
43.33
17,761,481
100.00
17,761,581
100.00
17,769,881
100.00
17,761,481
100.00
17,769,881
100.00
17,778,481
100.00
53.70
56.61
56.64
53.70
56.64
56.67
Status of Investor Complaints as at 31st December, 2013
Pending as on 01-10-2013
Received during the quarter
Resolved during the quarter
Pending as on 31-12-2013
Nil
96
96
Nil
V.C. Nannapaneni
Chairman & Managing Director
____________________________________________________________________________________________________________________________________________________
Regd. Office: N ATCO House, Road # 2, Banjara Hills, Hyderabad : 500 033.
Statement of consolidated Financial Results for the quarter ended 31st December, 2013
Rs. lakhs
PART I : STATEMENT OF CONSOLIDATED RESULTS
THREE MONTHS ENDED
(UNREVIEWED/UNAUDITED)
PARTICULARS
31-DEC-2013
01. Gross Sales / Income from Operations
Less : Excise Duty
Less : Sales Tax
Net Sales / Income from Operations
02. Other Operating Income
03. TOTAL INCOME FROM OPERATIONS
04. EXPENDITURE
a) Cost of materials consumed
b) Purchases of stock-in-trade
c) Changes in inventories of finished goods, work-inprogress and stock-in-trade
d) Employee benefits expense
e) Depreciation and amortization expense
f) Other Expenses
TOTAL EXPENSES
05. Profit / (Loss) from Operations before other income,
finance costs and exceptional items
06. Other Income
07. Finance costs
08. Exceptional Item
09. Profit / (Loss) from ordinary activities before tax
10. Tax expense, including deferred tax
11. Minority Interest
12. Net Profit / Loss (-) from ordinary activities after tax
13. Paid-up Equity Share Capital (each share of Rs. 10/face value)
14. Reserves excluding revaluation reserves as per
Balance Sheet of previous accounting year
15. Earnings per share – Basic and diluted EPS before
and after extraordinary item (Rs.) – non-annualized
16. Public Shareholding:
a) Number of Shares
b) Percentage of Shareholding
16. Promoters and Promoter Group Shareholding
a) Pledged / Encumbered – No. of shares
b) Non – encumbered – No. of shares
Percentage (as a % of the total shareholding of
promoter and promoter group)
Percentage (as a % of the total share
capital of the company)
30-SEP-2013
31-DEC-2012
YEAR-TO-DATE FIGURES
(UNREVIEWED/UNAUDITED) FOR
THE NINE MONTHS PERIOD
ENDED ON
YEAR ENDED
(AUDITED)
31-DEC-2013
31-MAR-2013
31-DEC-2012
19260
321
321
18618
1718
20336
16952
390
271
16291
1631
17922
16515
508
229
15778
1983
17761
53275
1035
877
51363
4146
55509
49146
1692
823
46631
3039
49670
65302
2122
1101
62079
4322
66401
6699
-
6013
-
7153
55
18457
-
19604
488
17757
8714
-908
2976
770
6177
15714
4622
-227
2633
747
5155
14321
3601
-527
2447
634
4109
13871
3890
-1410
8198
2248
16056
43549
11960
-1436
7690
1587
11756
39689
9981
-2191
10229
2212
16900
53621
12780
127
922
3827
1082
-243
2988
3307
198
1002
2797
371
-266
2692
3137
593
758
541
3184
1061
-136
2259
3137
675
2920
9715
2453
-610
7872
3307
1055
1808
1159
8069
2323
-308
6054
3137
1241
2631
1158
10232
3644
-599
7187
3137
9.34
9.34
8.58
8.58
7.20
7.20
24.94
24.94
19.30
19.30
50217
23.01
22.91
15,311,593
46.30
-
13,611,493
43.39
-
13,603,193
43.36
-
15,311,593
46.30
-
13,603,193
43.36
-
13,594,593
43.33
-
17,761,481
100.00
17,761,581
100.00
17,769,881
100.00
17,761,481
100.00
17,769,881
100.00
17,778,481
100.00
53.70
56.61
56.64
53.70
56.64
56.67
The stand-alone results are available on the company’s web-site www.natcopharma.co.in. The Board of Directors have recommended an interim dividend of Rs. 5/- per equity share,
payable on 6th March, 2014.
Dated at Hyderabad, this, the 13th February, 2014.
for and on behalf of the Board of Directors,
NATCO Pharma Limited
Status of Investor Complaints as at 31st December, 2013
Pending as on 01-10-2013
Received during the quarter
Resolved during the quarter
Pending as on 31-12-2013
Nil
96
96
Nil
V.C. Nannapaneni
Chairman & Managing Director
____________________________________________________________________________________________________________________________________________________
Regd. Office: N ATCO House, Road # 2, Banjara Hills, Hyderabad : 500 033.
Report of segment wise revenue, Results and Capital Employed, (Un-audited) under Clause
41 of the Listing Agreement, for the quarter and nine months ended on 31st December, 2013
5 Vlakhs
THREE MONTHS ENDED
01. Segment Revenue (Net)
a)
Bulk Chemicals
b)
Formulations
c)
Job Work
d)
Unallocated
Total
Less : Inter-segment Revenue
Net Sales / Income from Operations
02. Segment Results : Profit (+)/Loss (-) before
tax and interest
a)
Bulk Chemicals
b)
c)
d)
Formulations
Job Work
Unallocated
Total
Less : a) Interest
b) Oher unallocable expenditure
c) Unallocable income
Total Profit Before Tax
03. Capital Employed (Segment Assets –
Segment Liabilities)
a)
Bulk Chemicals
b)
Formulations
c)
Job Work
e)
Unallocated (Others)
Total
PREVIOUS
ACCOUNTING
YEAR ENDED
(UN-AUDITED)
NINE MONTHS ENDED
31-DEC-2013
30-SEP-2013
31-DEC-2012
31-DEC-2013
31-DEC-2012
31-MAR-2013
5827
11667
343
230
18067
644
17423
5570
9616
418
38
15642
636
15006
6743
6982
255
1391
15371
340
15031
17757
27771
956
2123
48607
1696
46911
17130
21795
725
2990
42640
1046
41594
23692
29367
944
3244
57247
1322
55925
1509
5298
311
204
7322
877
2185
105
4365
1051
4474
332
21
5878
957
1871
177
3227
1614
2531
208
1253
5606
731
1958
570
3487
4077
11958
782
1912
18729
2792
5717
632
10852
3986
9099
599
2692
16376
1742
6692
991
8933
5527
12235
728
2915
21405
2512
8855
1194
11232
40010
36689
236
-3940
72995
37017
35170
295
-13468
59014
37939
31251
48
-16688
52550
40010
36689
236
-3940
72995
37939
31251
48
-16688
52550
36375
32742
94
-15453
53758
The above un-audited financial results were reviewed by the Audit Committee, Statutory Auditors and approved by the Board of Directors at a meeting held at Hyderabad, on
Thursday, the 13th February, 2014. In respect of non-accounting of minimum alternate tax credit, referred to in the review report, the company will evaluate the position during the
current financial year. Figures for the previous period(s) have been re-arranged / re-grouped wherever necessary. Exceptional item represents amount written off against a pending
legal dispute. Employee benefit expenses for the nine months ended 31st December, 2012 include Rs. 362 lakhs pertaining to stock options vested during the earlier period. The
stand-alone results are available on the company’s web-site www.natcopharma.co.in. The Board of Directors have recommended an interim dividend of Rs.5 per equity share, (Rs.
4 per equity share during nine months ended 31st December, 2012) payable on 6th March, 2014. During the quarter, the company had allotted, on a preferential basis, 17 lakh
equity shares of Rs. 10/- each, at a premium of Rs. 628.40 per share, to CX Securities Limited.
Dated at Hyderabad, this, the 13th day of February, 2014.
for and on behalf of the Board of Directors,
NATCO Pharma Limited
V.C. Nannapaneni
Chairman & Managing Director
_______________________________________________________________________________________________________________________________________________
Regd. Office: N ATCO House, Road # 2, Banjara Hills, Hyderabad : 500 033.